Stock Analysis
Enzymatica First Quarter 2024 Earnings: kr0.11 loss per share (vs kr0.091 loss in 1Q 2023)
Enzymatica (STO:ENZY) First Quarter 2024 Results
Key Financial Results
- Revenue: kr9.42m (down 28% from 1Q 2023).
- Net loss: kr18.9m (loss widened by 26% from 1Q 2023).
- kr0.11 loss per share (further deteriorated from kr0.091 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Enzymatica Earnings Insights
Looking ahead, revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Pharmaceuticals industry in Sweden.
Performance of the Swedish Pharmaceuticals industry.
The company's shares are down 4.1% from a week ago.
Risk Analysis
We should say that we've discovered 6 warning signs for Enzymatica that you should be aware of before investing here.
Valuation is complex, but we're helping make it simple.
Find out whether Enzymatica is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:ENZY
Enzymatica
Enzymatica AB (publ), a life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract.
Mediocre balance sheet with limited growth.